What is the 13F Pro Quality Score for HURA?

13F Pro ranks TuHURA Biosciences, Inc./NV (HURA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View HURA's current score at https://13fpro.ai/research/HURA (free sign-up required for the full ranking).

Where does 13F Pro source HURA data?

All TuHURA Biosciences, Inc./NV fundamentals and ownership data come directly from SEC EDGAR. TuHURA Biosciences, Inc./NV files with the SEC under CIK 1498382. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is HURA in?

TuHURA Biosciences, Inc./NV (HURA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is HURA research updated on 13F Pro?

HURA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

TuHURA Biosciences, Inc./NV(HURA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1498382 HURA stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

HURA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for TuHURA Biosciences, Inc./NV (HURA), a Healthcare sector company. HURA is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q3 2026), TuHURA Biosciences, Inc./NV reports net income of $-7.5M, free cash flow of $-4.5M. Top institutional holders of HURA by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. HURA trades on the Nasdaq exchange and files with the SEC under CIK 1498382. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HURA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TuHURA Biosciences, Inc./NV directly from SEC EDGAR.

Revenue

Q3 2026

$0.00

Net Income

Q3 2026

$-7.5M

Free Cash Flow

Q3 2026

$-4.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+43.2% YoY

$-8.3MFY 2024

FY20 $-9.1MFY21 $-38.3MFY23 $-14.6MFY24 $-8.3M

EPS (Diluted)

—FY 2024

FY20 —FY21 —FY23 —FY24 —

Total Assets

+55.9% YoY

$6.2MFY 2024

FY20 $2.9MFY21 $13.5MFY23 $4.0MFY24 $6.2M

Total Debt

—FY 2024

FY20 —FY21 —FY23 —FY24 —

Op. Cash Flow

+39.5% YoY

$-7.2MFY 2024

FY20 $-7.9MFY21 $-18.9MFY23 $-11.9MFY24 $-7.2M

Metric	FY 2024	FY 2023	FY 2021	FY 2020	FY 2019	FY 2015
Net Income	$-8.3M +43.2%	$-14.6M +61.7%	$-38.3M -319.7%	$-9.1M -13.4%	$-8.0M -85.1%	$-4.3M
EPS (Diluted)	—	—	—	—	—	$0.01
Total Assets	$6.2M +55.9%	$4.0M -70.6%	$13.5M +361.0%	$2.9M -27.2%	$4.0M +56.8%	$2.6M
Total Debt	—	—	—	—	—	$1.0M
Operating Cash Flow	$-7.2M +39.5%	$-11.9M +37.1%	$-18.9M -137.9%	$-7.9M -25.3%	$-6.3M -64.2%	$-3.9M

AI Insight: HURA Financial Trends

Pre-revenue biotech burning cash at ~$6–8M quarterly with equity base eroding despite fundraising.

• Net losses stabilized at $7–10M per quarter from Q1 2025 onward, after $16M loss in Q4 2024.

• Operating cash burn remains negative and persistent ($4–11M quarterly), with no revenue generation.

• Equity balance deteriorated from $23M in Q1 2026 baseline, reflecting ongoing losses and negative FCF.

⚠ Operating cash burn spiked to $11M in Q3 2025 — highest on record. Recent moderation to $4M in Q1 2026 requires confirmation.

⚠ No revenue reported across all 8 quarters. Runway sustainability and catalyst timeline critical.

AI Insight: HURA Ratio Trends

HURA remains unprofitable with persistently negative ROE, showing no recovery trajectory across available metrics.

• ROE deteriorated to -195.9% in Q2 2025 before stabilizing around -130% by Q1 2026, indicating sustained losses.

• ROA turned negative at -98.9% in Q4 2025, confirming asset-base erosion from ongoing net losses.

⚠ Operating and net profit margins absent across all periods; inability to measure operational efficiency signals fundamental profitability challenge.

⚠ No ROIC data available; absence of capital return metrics limits visibility into whether cash burn is sustainable.

Get alerted when HURA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for TuHURA Biosciences, Inc./NV including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of HURA

BlackRock, Inc.
$4.4M2,450,256 sh
VANGUARD CAPITAL MANAGEMENT LLC
$3.7M2,074,228 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.8M986,922 sh
AQR CAPITAL MANAGEMENT LLC
$1.1M607,168 sh
STATE STREET CORP
$918.1K512,913 sh
NORTHERN TRUST CORP
$533.8K298,187 sh
VANGUARD FIDUCIARY TRUST CO
$514.0K287,133 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$454.0K253,641 sh
Bank of New York Mellon Corp
$378.7K211,568 sh
Apollon Wealth Management, LLC
$282.8K158,010 sh

Fund	Value	Shares
BlackRock, Inc.	$4.4M	2,450,256
VANGUARD CAPITAL MANAGEMENT LLC	$3.7M	2,074,228
GEODE CAPITAL MANAGEMENT, LLC	$1.8M	986,922
AQR CAPITAL MANAGEMENT LLC	$1.1M	607,168
STATE STREET CORP	$918.1K	512,913
NORTHERN TRUST CORP	$533.8K	298,187
VANGUARD FIDUCIARY TRUST CO	$514.0K	287,133
VANGUARD PORTFOLIO MANAGEMENT LLC	$454.0K	253,641
Bank of New York Mellon Corp	$378.7K	211,568
Apollon Wealth Management, LLC	$282.8K	158,010

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put HURA on your watchlist

Track score changes the day TuHURA Biosciences, Inc./NV files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is HURA a good stock to buy?

13F Pro's AI-powered analysis of TuHURA Biosciences, Inc./NV (HURA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for HURA are available on the HURA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own HURA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling HURA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of TuHURA Biosciences, Inc./NV's investment landscape.